Predisposing factors of diminished survival in simultaneous liver/kidney transplantation

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 2966-2973

  Hibi, T ^a,b   Sageshima, J ^a,b   Molina, E ^a,b   Ciancio, G ^a,b   Nishida, S ^a,b   Chen, L ^a,b   Arosemena, L ^a,b   Mattiazzi, A ^a,b   Guerra, G ^a,b   Kupin, W ^a,b   Tekin, A ^a,b   Selvaggi, G ^a,b   Levi, D ^a,b   Ruiz, P ^a,b   Livingstone, A S ^a,b   Roth, D ^a,b   Martin, P ^a,b   Tzakis, A ^a,b   Burke, G W ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Combined transplants; hepatitis C virus; kidney transplantation; liver transplantation; survival

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; DELAYED GRAFT FUNCTION; DISEASE PREDISPOSITION; DONOR SELECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT INFECTION; RENAL GRAFT DYSFUNCTION; RISK FACTOR; SEX DIFFERENCE; SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; CAUSALITY; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84868214307     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04121.x     Document Type: Article

References (54)

1. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ,. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-1019.
2. Papafragkakis H, Martin P, Akalin E,. Combined liver and kidney transplantation. Curr Opin Organ Transplant 2010; 15: 263-268.
3. Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD,. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 2008; 8: 2243-2251.
4. Davis CL, Feng S, Sung R, et al,. Simultaneous liver-kidney transplantation: Evaluation to decision making. Am J Transplant 2007; 7: 1702-1709.
5. Locke JE, Warren DS, Singer AL, et al,. Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: Ineffective usage of renal allografts. Transplantation 2008; 85: 935-942.
6. Hanish SI, Samaniego M, Mezrich JD, et al,. Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: A preliminary report. Transplantation 2010; 90: 52-60.
7. Kiberd B, Skedgel C, Alwayn I, Peltekian K,. Simultaneous liver kidney transplantation: A medical decision analysis. Transplantation 2011; 91: 121-127.
8. Ruiz R, Jennings LW, Kim P, et al,. Indications for combined liver and kidney transplantation: Propositions after a 23-year experience. Clin Transplant 2010; 24: 807-811.
9. Chava SP, Singh B, Stangou A, et al,. Simultaneous combined liver and kidney transplantation: a single center experience. Clin Transplant 2010; 24: E62-E68.
10. Mehrabi A, Fonouni H, Ayoub E, et al,. A single center experience of combined liver kidney transplantation. Clin Transplant 2009; 23: 102-114.
11. Ruiz R, Kunitake H, Wilkinson AH, et al,. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-742.
12. Creput C, Durrbach A, Samuel D, et al,. Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant 2003; 3: 348-356.
13. de la Cerda F, Jimenez WA, Gjertson DW, Venick R, Tsai E, Ettenger R,. Renal graft outcome after combined liver and kidney transplantation in children: UCLA and UNOS experience. Pediatr Transplant 2010; 14: 459-464.
14. Rana A, Robles S, Russo MJ, et al,. The combined organ effect: protection against rejection? Ann Surg 2008; 248: 871-879.
15. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL,. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation 2006; 82: 1298-1303.
16. Fong TL, Bunnapradist S, Jordan SC, Selby RR, Cho YW,. Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation. Transplantation 2003; 76: 348-353.
17. Barth RN, Campos L, Kukuruga DL, Drachenberg C, Philosophe B,. Antibody-mediated rejection of renal allograft in combined liver-kidney transplant. Clin Transplant 2010; 24: 685-690.
18. Reichman TW, Marino SR, Milner J, et al,. Acute humoral rejection in an ABO compatible combined liver-kidney transplant-the kidney is not always protected. Am J Transplant 2009; 9: 1957-1960.
19. Katznelson S, Cecka J,. The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor. Transplantation 1996; 61: 1403-1423.
20. Levey AS, Coresh J, Greene T, et al,. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
21. Intraovserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
22. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244-251.
23. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-465.
24. Ciancio G, Burke GW, Gaynor JJ, et al,. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: One year follow-up. Transplantation 2008; 86: 67-74.
25. Roth D, Gaynor JJ, Reddy KR, et al,. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152-1160.
26. del Pozo AC, Martín JD, Rodriguez-Laiz G, et al,. Outcome of combined liver and kidney transplantation in hepatitis C: A single-center long-term follow-up experience. Transplant Proc 2009; 41: 1713-1716.
27. Van Wagner LB, Baker T, Ahya SN, Norvell JP, Wang E, Levitsky J,. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol 2009; 51: 874-880.
28. Patel SJ, Duhart BT Jr, Krauss AG, et al,. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Transplantation 2008; 86: 313-320.
29. Siddiqi N, McBride MA, Hariharan S,. Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004; 65: 1906-1913.
30. Doshi MD, Garg N, Reese PP, Parikh CR,. Recipient risk factors associated with delayed graft function: A paired kidney analysis. Transplantation 2011; 91: 666-671.
31. Parekh J, Bostrom A, Feng S,. Diabetes mellitus: A risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transplant 2010; 10: 298-303.
32. Askar M, Schold JD, Eghtesad B, et al,. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation 2011; 91: 1286-1292.
33. O'Riordan A, Donaldson N, Cairns H, et al,. Risk score predicting decline in renal function postliver transplant: Role in patient selection for combined liver kidney transplantation. Transplantation 2010; 89: 1378-1384.
34. Cerny A,. Hepatitis C after simultaneous liver-kidney transplantation. J Hepatol 2009; 51: 839-841.
35. Cosio FG, Sedmak DD, Henry ML, et al,. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1571-1576.
36. Roth D, Cirocco R, Zucker K, et al,. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59: 1676-1682.
37. Cruzado JM, Carrera M, Torras J, Grinyõ JM,. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1: 171-178.
38. Cruzado JM, Gil-Vernet S, Ercilla G, et al,. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996; 7: 2469-2475.
39. Kendrick EA, McVicar JP, Kowdley KV, et al,. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997; 63: 1287-1293.
40. Abrahamian GA, Cosimi AB, Farrell ML, Schoenfeld DA, Chung RT, Pascual M,. Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation. Liver Transpl 2000; 6: 185-190.
41. Chazouilleres O, Kim M, Combs C, et al,. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-999.
42. Gane EJ, Portmann BC, Naoumov NV, et al,. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
43. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al,. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-1130.
44. Pascual M, Thadhani R, Chung RT, et al,. Nephrotic syndrome after liver transplantation in a patient with hepatitis C virus-associated glomerulonephritis. Transplantation 1997; 64: 1073-1076.
45. Bahra M, Neumann UI, Jacob D, et al,. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005; 5: 406-411.
46. Germani G, Pleguezuelo M, Villamil F, et al,. Azathioprine in liver transplantation: A reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009; 9: 1725-1731.
47. McKenna GJ, Trotter JF, Klintmalm E, et al,. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
48. Gane EJ,. Diabetes mellitus following liver transplantation in patients with hepatitis C Virus: Risks and consequences. Am J Transplant 2012; 12: 531-538.
49. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyõ JM,. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360.
50. Domínguez-Gil B, Morales JM,. Transplantation in the patient with hepatitis C. Transpl Int 2009; 22: 1117-1131.
51. Pageaux GP, Hilleret MN, Garrigues V, et al,. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: An open pilot study. Transpl Int 2009; 22: 562-567.
52. Pawlotsky JM,. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011; 140: 746-754.
53. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, et al,. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 1051-1057.
54. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.